한글목차

세계 표적 인간화 마우스 시장의 미래는 암 연구, 면역치료, 약물 스크리닝 시장에서 기회가 있으며, 유망한 시장으로 평가받고 있습니다. 세계 표적 인간화 마우스 시장은 2025년부터 2031년까지 8.9%의 연평균 성장률을 보일 것으로 예상됩니다. 이 시장의 주요 촉진요인은 맞춤형 치료에 대한 수요 증가와 유전자 편집 기술의 발전입니다.

• Lucintel은 유형별로는 면역 체크포인트가 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상하고 있습니다.
• 용도별로는 암 연구가 가장 높은 성장이 예상됩니다.
• 지역별로는 아시아태평양이 예측 기간 동안 가장 높은 성장을 보일 것으로 예상됩니다.

표적 인간화 마우스 시장의 새로운 동향

유전공학의 발전, 정밀의료에 대한 수요 증가, 보다 정확한 전임상 모델에 대한 수요 증가 등을 배경으로 표적 인간화 마우스 시장은 빠르게 발전하고 있습니다. 이러한 추세는 생물의학 연구 분야를 재구성하고, 의약품 개발, 맞춤형 의료, 질병 이해를 위한 새로운 기회를 제공하고 있습니다. 다음은 시장에 영향을 미치는 5가지 주요 트렌드입니다.

• 유전자 편집 기술(CRISPR 등)의 발전 : CRISPR과 같은 유전자 편집 기술은 인간화 마우스 제작에 혁명을 가져왔으며, 유전자의 정확한 변형과 인간 세포 및 조직의 편입을 가능하게 하고 있습니다. 이러한 발전으로 인간화 마우스 모델의 정확도가 비약적으로 향상되어 전임상시험의 신뢰성이 높아졌습니다. 그 결과, 인간화 마우스 시장은 확대되었고, 연구자들은 암, 자가면역질환, 감염성 질환 등의 질병 연구를 위해 보다 특이적인 모델을 만들 수 있게 되었습니다.
• 맞춤형 의료에 대한 수요 증가 : 맞춤형 의료는 표적 인간화 마우스 시장의 주요 촉진요인 중 하나이며, 인간화 모델은 약물에 대한 개인별 반응을 보다 정확하게 예측할 수 있습니다. 제약 업계와 생명공학업계가 맞춤형 치료제 개발에 집중하는 가운데, 인간 고유의 질병 기전 및 약물 반응을 연구하기 위한 인간화 마우스의 필요성이 높아지고 있습니다. 이러한 추세는 다양한 인간의 유전적 배경과 질병 프로파일을 모방할 수 있는 고도의 인간화 모델에 대한 큰 수요를 창출하고 있습니다.
• 전임상시험의 확대 : 인간화 마우스는 전임상시험에서 필수적인 도구가 되고 있으며, 기존 동물 모델보다 더 신뢰할 수 있는 결과를 제공하고 있습니다. 이러한 추세는 인간의 반응을 보다 정확하게 예측할 수 있는 고품질 시험 모델에 대한 요구가 증가함에 따라 더욱 가속화되고 있습니다. 인간화 마우스는 면역치료, 생물학적 제제, 유전자 기반 치료의 시험에서 특히 가치가 높습니다. 전임상시험에 대한 규제 요건이 강화됨에 따라 의약품 개발에서 인간화 마우스 모델에 대한 수요는 계속 증가할 것으로 예상됩니다.
• 생명공학 및 제약 연구에 대한 투자 증가 : 생명공학 및 제약 연구에 대한 관심이 높아지면서 첨단 연구 모델, 특히 인간화 마우스에 대한 수요가 증가하고 있습니다. 정부, 학계, 민간기업은 생명과학에 많은 투자를 하고 있으며, 그 결과 인간화 동물 모델의 기술 혁신이 더욱 촉진되고 있습니다. 이러한 투자는 보다 정교하고 신뢰할 수 있으며 확장 가능한 인간화 마우스의 개발로 이어져 생물 의학 연구와 신약 개발 과정을 가속화할 수 있습니다.
• 윤리적 고려와 규제 : 인간화 마우스의 사용이 확대됨에 따라, 그 제작과 연구 사용을 둘러싼 윤리적 문제가 대두되고 있습니다. 이에 따라 유전자 변형 동물의 사용에 대한 규제와 가이드라인이 더욱 엄격하게 개발되고 있습니다. 연구자들은 현재 인간화 생쥐가 책임감 있게 사용되어 동물의 고통을 최소화하는 데 중점을 두고 있습니다. 이러한 추세는 연구 활동의 투명성을 높이고, 보다 지속가능하고 윤리적인 모델 개발을 촉진하고 있습니다.

이러한 새로운 추세는 유전공학의 혁신, 맞춤형 의료에 대한 관심 증가, 생명공학에 대한 투자 증가 등에 힘입어 표적 인간화 마우스 시장이 빠르게 성장하고 있다는 것을 보여줍니다. 이러한 추세는 계속 진화하고 있으며, 생물 의학 연구 수행 방법을 재구성하고 보다 정확하고 효율적인 전임상 모델 개발을 촉진하고 있습니다.

표적 인간화 마우스 시장의 최근 동향

최근 표적 인간화 마우스 시장의 동향은 유전공학의 비약적인 발전, 신약개발에 대한 새로운 응용, 연구자금의 증가 등 큰 변화를 가져오고 있습니다. 이러한 개발로 인해 인간화 마우스는 정밀의료, 질병 모델링, 약물 시험에서 중요한 도구로 자리매김하고 있습니다. 다음은 시장을 형성하고 있는 5가지 주요 발전입니다.

• CRISPR-Cas9과 고급 유전자 편집 : CRISPR-Cas9 기술의 채택은 인간화 마우스 시장에 큰 영향을 미치고 있습니다. 이 기술을 통해 정확하고 효율적인 유전자 편집이 가능해졌고, 연구자들은 보다 정확하고 인간과 유사한 모델을 만들 수 있게 되었습니다. 인간의 유전자, 세포, 조직을 마우스에 정밀하게 도입할 수 있게 되면서 특정 질환 연구나 신약 후보물질 시험에 특화된 인간화 마우스 제작이 가속화되고 있습니다.
• 면역종양학 연구와 인간화 마우스 : 면역종양학 연구에서 인간화 마우스는 암 면역요법을 시험하기 위해 점점 더 많이 사용되고 있습니다. 이러한 모델은 인간의 면역 체계를 더 잘 표현하고, 면역 치료 및 항암제 전임상시험을 더 정확하게 수행 할 수 있습니다. 면역 종양학의 부상은 인간화 마우스 모델에 대한 수요를 증가시켰고, 그 생산과 암 연구에 대한 응용을 더욱 발전시키고 있습니다.
• 감염병 연구를 위한 인간화 마우스 : 인간화 마우스는 HIV, 지카바이러스 등 바이러스 감염증을 포함한 감염병 연구에 있어 매우 중요한 존재로 자리 잡고 있습니다. 이러한 모델은 연구자들에게 백신, 항바이러스제, 기타 치료제를 보다 인간에 가까운 환경에서 시험할 수 있는 능력을 제공합니다. 전 세계적으로 전염병 및 감염병 확산에 대한 우려가 높아지면서 감염병 연구를 위한 인간화 마우스에 대한 수요가 빠르게 증가하고 있습니다.
• 생명공학기업과 연구기관의 파트너십 : 생명공학기업과 학술연구기관과의 협력을 통해 인간화 마우스 모델의 개발 및 적용이 진행되고 있습니다. 이러한 파트너십을 통해 인간화 마우스의 기술 혁신과 상용화가 가속화되고 있으며, 신약개발, 질병 연구, 정밀의료에 대한 활용이 확대되고 있습니다. 이러한 협력 관계는 차세대 인간화 마우스 모델을 개발하는 데 있어 매우 중요합니다.
• 보다 비용 효율적인 인간화 마우스 모델 개발 : 인간화 마우스를 제작하고 유지하기 위한 보다 비용 효율적인 방법이 개발되고 있습니다. 여기에는 번식 기술 향상, 유전자 변형, 모델 표준화 등이 포함됩니다. 이러한 모델에 대한 수요가 증가함에 따라 비용 효율성이 우선순위가 되어 연구 기관과 생명공학 기업 전반에 걸쳐 더 광범위하게 채택될 수 있을 것입니다.

표적 인간화 마우스 시장의 주요 발전은 생물 의학 연구 발전에서 이러한 모델의 중요성이 증가하고 있음을 뒷받침합니다. 유전자 편집의 혁신, 면역종양학 연구에 대한 수요 증가, 산학협력은 보다 정확하고 비용 효율적이며 특수한 인간화 마우스 모델 개발로 이어져 시장을 주도하고 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 거시경제 동향과 예측
• 업계 성장 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 유형별 세계의 표적 인간화 마우스 시장

• 개요
• 유형별 매력 분석
• 종양 표적 : 동향과 예측(2019-2031년)
• 면역 체크포인트 : 동향과 예측(2019-2031년)
• 보체 시스템 표적 : 동향과 예측(2019-2031년)
• 대사 표적 : 동향과 예측(2019-2031년)
• 기타 : 동향과 예측(2019-2031년)

제5장 용도별 세계의 표적 인간화 마우스 시장

• 개요
• 용도별 매력 분석
• 암 조사 : 동향과 예측(2019-2031년)
• 면역요법 : 동향과 예측(2019-2031년)
• 약물 스크리닝 : 동향과 예측(2019-2031년)

제6장 지역 분석

• 개요
• 지역별 세계 표적 인간화 마우스 시장

제7장 북미의 표적 인간화 마우스 시장

• 개요
• 북미의 표적 인간화 마우스 시장(유형별)
• 북미의 표적 인간화 마우스 시장(용도별)
• 미국의 표적 인간화 마우스 시장
• 멕시코의 표적 인간화 마우스 시장
• 캐나다의 표적 인간화 마우스 시장

제8장 유럽의 표적 인간화 마우스 시장

• 개요
• 유럽의 표적 인간화 마우스 시장(유형별)
• 유럽의 표적 인간화 마우스 시장(용도별)
• 독일의 표적 인간화 마우스 시장
• 프랑스의 표적 인간화 마우스 시장
• 스페인의 표적 인간화 마우스 시장
• 이탈리아의 표적 인간화 마우스 시장
• 영국의 표적 인간화 마우스 시장

제9장 아시아태평양의 표적 인간화 마우스 시장

• 개요
• 아시아태평양의 표적 인간화 마우스 시장(유형별)
• 아시아태평양의 표적 인간화 마우스 시장(용도별)
• 일본의 표적 인간화 마우스 시장
• 인도의 표적 인간화 마우스 시장
• 중국의 표적 인간화 마우스 시장
• 한국의 표적 인간화 마우스 시장
• 인도네시아의 표적 인간화 마우스 시장

제10장 기타 지역의 표적 인간화 마우스 시장

• 개요
• 기타 지역의 표적 인간화 마우스 시장(유형별)
• 기타 지역의 표적 인간화 마우스 시장(용도별)
• 중동의 표적 인간화 마우스 시장
• 남미의 표적 인간화 마우스 시장
• 아프리카의 표적 인간화 마우스 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
  • 경쟁 기업 간의 경쟁 관계
  • 구매자의 교섭력
  • 공급 기업의 교섭력
  • 대체품의 위협
  • 신규 참여업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 유형별 성장 기회
  • 용도별 성장 기회
• 세계의 표적 인간화 마우스 시장의 최신 동향
• 전략 분석
  • 신제품 개발
  • 인증과 라이선싱
  • 합병, 인수, 계약, 제휴, 합작투자

제13장 밸류체인 전체에 걸친 주요 기업 개요

• Competitive Analysis
• Charles River
• Jackson Laboratory
• Taconic Biosciences
• Gempharmatech
• Vitalstar Biotechnology
• GenOway
• Hanheng Biotechnology
• Cyagen Biosciences
• Beijing Biocytogen
• Shanghai Model Organisms Center

제14장 부록

• 그림목차
• 표목차
• 조사 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• 회사 소개
• 문의

영문목차

The future of the global target humanized mice market looks promising with opportunities in the cancer research, immunity therapy, and drug screening markets. The global target humanized mice market is expected to grow with a CAGR of 8.9% from 2025 to 2031. The major drivers for this market are the increasing demand for personalized treatment and the rising advancement in gene editing technologies.

• Lucintel forecasts that, within the type category, immune checkpoint is expected to witness the highest growth over the forecast period.
• Within the application category, cancer research is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Target Humanized Mice Market

The target humanized mice market is evolving rapidly, driven by advancements in genetic engineering, increased demand for precision medicine, and the growing need for more accurate preclinical models. These trends are reshaping the field of biomedical research, offering new opportunities for drug development, personalized medicine, and disease understanding. Below are five key trends that are influencing the market.

• Advances in Gene Editing Technologies (e.g., CRISPR): Gene editing technologies like CRISPR are revolutionizing the production of humanized mice, allowing for precise modifications of genes and the incorporation of human cells or tissues. These advancements have dramatically improved the accuracy of humanized mice models, making them more reliable for preclinical testing. As a result, the market for humanized mice is expanding, with researchers able to create more specific models for disease research, including cancer, autoimmune disorders, and infectious diseases.
• Growing Demand for Personalized Medicine: Personalized medicine is one of the key drivers of the target humanized mice market, as humanized models offer more accurate predictions of individual responses to drugs. As the pharmaceutical and biotechnology industries focus on developing tailored therapies, the need for humanized mice to study human-specific disease mechanisms and drug responses is growing. This trend is creating significant demand for advanced humanized models that can mimic diverse human genetic backgrounds and disease profiles.
• Expansion of Preclinical Drug Testing: Humanized mice are becoming essential tools in preclinical drug testing, providing more reliable results than traditional animal models. This trend is fueled by the increasing need for high-quality testing models that can predict human responses more accurately. Humanized mice are particularly valuable in the testing of immunotherapies, biologics, and gene-based treatments. As regulatory requirements for preclinical testing become more stringent, the demand for humanized mice models in drug development is expected to continue growing.
• Rising Investments in Biotech and Pharmaceutical Research: The increasing focus on biotechnology and pharmaceutical research is driving the demand for advanced research models, particularly humanized mice. Governments, academic institutions, and private enterprises are investing heavily in life sciences, resulting in a greater push for innovations in humanized animal models. These investments are leading to the development of more advanced, reliable, and scalable humanized mice, which in turn are accelerating biomedical research and drug discovery processes.
• Ethical Considerations and Regulations: As the use of humanized mice expands, ethical concerns surrounding their creation and use in research are becoming more prominent. This has led to the development of stricter regulations and guidelines for using genetically modified animals. Researchers are now focused on ensuring that humanized mice are used responsibly, emphasizing minimizing animal suffering. This trend encourages the development of more sustainable and ethical models with greater transparency in research practices.

These emerging trends highlight the rapid growth of the target humanized mice market, fueled by innovations in genetic engineering, a growing emphasis on personalized medicine, and increased investments in biotechnology. As these trends continue to evolve, they are reshaping how biomedical research is conducted and driving the development of more accurate and efficient preclinical models.

Recent Developments in the Target Humanized Mice Market

Recent developments in the target humanized mice market have been transformative, with breakthroughs in genetic engineering, new applications in drug discovery, and increased research funding. These developments are positioning humanized mice as critical tools in precision medicine, disease modeling, and drug testing. Below are five key developments that are shaping the market.

• CRISPR-Cas9 and Advanced Genetic Editing: The adoption of CRISPR-Cas9 technology has significantly impacted the humanized mice market. This technology allows for precise and efficient gene editing, enabling researchers to create more accurate and human-relevant models. The ability to introduce human genes, cells, or tissues into mice with high precision has accelerated the creation of specialized humanized mice for studying specific diseases and testing new drug candidates.
• Immuno-oncology Research and Humanized Mice: Humanized mice are increasingly being used in immuno-oncology research to test cancer immunotherapies. These models are more representative of human immune systems, allowing for more accurate preclinical testing of immunotherapies and cancer drugs. The rise of immuno-oncology has driven demand for humanized mice models, leading to further developments in their production and application in cancer research.
• Humanized Mice for Infectious Disease Research: Humanized mice have become crucial in the study of infectious diseases, including viral infections like HIV and Zika virus. These models offer researchers the ability to test vaccines, antivirals, and other therapeutic agents in a more human-like context. With the rising global concern over pandemics and infectious disease outbreaks, the demand for humanized mice for infectious disease research has grown rapidly.
• Partnerships Between Biotech Companies and Research Institutions: Collaborations between biotech companies and academic research institutions have led to advancements in the development and application of humanized mice models. These partnerships are accelerating the innovation and commercialization of humanized mice, expanding their use in drug discovery, disease research, and precision medicine. These collaborations are crucial for advancing the next generation of humanized mouse models.
• Development of More Cost-Effective Humanized Mouse Models: There has been a push towards developing more cost-effective methods for creating and maintaining humanized mice. This includes improvements in breeding techniques, genetic modifications, and model standardization. As demand for these models increases, cost-effectiveness becomes a priority, allowing for broader adoption across research institutions and biotech companies.

The key developments in the target humanized mice market underscore the growing importance of these models in advancing biomedical research. Innovations in genetic editing, increased demand for immuno-oncology research, and partnerships between industry and academia are driving the market forward, leading to the development of more accurate, cost-effective, and specialized humanized mice models.

Strategic Growth Opportunities in the Target Humanized Mice Market

The target humanized mice market offers several growth opportunities across a variety of applications, driven by advancements in genetic engineering and the increasing need for precision models in drug testing and disease research. Below are five key growth opportunities by application that are shaping the future of the market.

• Cancer Drug Discovery: Humanized mice models are essential for the development and testing of cancer drugs, especially in immuno-oncology. As the focus on immunotherapy and personalized cancer treatments grows, the demand for humanized mouse models in this field is expected to increase. This presents significant growth opportunities for companies involved in the production and development of humanized mice tailored for cancer research.
• Personalized Medicine: With the increasing focus on personalized medicine, there is a growing need for humanized mice models that can simulate specific human disease conditions. These models can be used to test individualized therapies, including gene therapies and targeted drugs. The demand for precision medicine is expected to drive the market for humanized mice, offering new growth avenues for model development and customization.
• Regenerative Medicine Research: Humanized mice models are being used to study regenerative medicine, particularly in areas like stem cell research and tissue engineering. These models provide insights into human tissue regeneration and repair mechanisms, supporting the development of regenerative therapies. This growing field offers substantial opportunities for the application of humanized mice in research.
• Infectious Disease Drug Development: The need for more accurate models to study infectious diseases, such as viral infections, is driving the growth of humanized mice in this application. Humanized models are becoming crucial tools for testing vaccines and antiviral therapies. This market segment is expected to expand as the demand for infectious disease treatments continues to rise.
• Toxicology and Safety Testing: Humanized mice models are increasingly being used in toxicology studies for drug safety testing. These models provide more relevant data on human drug responses, reducing the risks associated with human clinical trials. As regulatory agencies demand more human-relevant testing methods, the use of humanized mice in safety testing is expected to grow.

The strategic growth opportunities in the target humanized mice market are diverse, spanning cancer research, personalized medicine, regenerative therapies, infectious diseases, and safety testing. These applications are driving innovation in the market, with humanized mice models playing a critical role in advancing drug discovery and biomedical research.

Target Humanized Mice Market Driver and Challenges

The target humanized mice market is influenced by a range of technological, economic, and regulatory factors. Advances in biotechnology and genetic engineering have driven the development of humanized mouse models, which are essential for drug discovery and immunology research. Economic trends, such as increasing investment in life sciences and healthcare, further stimulate market growth. At the same time, regulatory factors, including ethical guidelines and animal welfare regulations, present challenges. Understanding the key drivers and challenges impacting this market is crucial for stakeholders to navigate the evolving landscape and harness the potential of humanized mice in biomedical research.

The factors responsible for driving the target humanized mice market include:

1. Advances in Biotechnology and Genetic Engineering: Technological advancements in biotechnology and genetic engineering are a major driver for the target humanized mice market. The development of more precise gene-editing technologies, such as CRISPR, has significantly improved the creation of humanized mouse models. These models are increasingly able to mimic human diseases more accurately, enhancing their utility in drug discovery, immunotherapy, and cancer research. As research requires more advanced and reliable animal models, the demand for humanized mice continues to rise, driving market growth and innovation in genetic engineering techniques.

2. Growing Pharmaceutical and Biotechnology Investments: The increasing investment in the pharmaceutical and biotechnology industries plays a critical role in driving demand for Target Humanized Mice. As drug discovery and development become more complex, humanized mice models are crucial in testing the efficacy and safety of new treatments. These models provide more reliable results than traditional animal models, accelerating the development process and reducing the time and cost of clinical trials. With growing investments in personalized medicine and immunotherapies, the need for humanized mice continues to expand, fostering growth in the market.

3. Demand for More Accurate Preclinical Models: There is a growing demand for more accurate and reliable preclinical models to improve the predictability of drug responses in humans. Traditional animal models often fail to replicate human physiology and disease mechanisms effectively, leading to high failure rates in clinical trials. Humanized mice, however, are better equipped to simulate human immune systems and disease conditions, providing more accurate data in preclinical testing. As a result, researchers and pharmaceutical companies are increasingly turning to humanized mice, driving market growth and the demand for innovative, high-quality models.

4. Increasing Focus on Immunotherapy and Personalized Medicine: The growing focus on immunotherapy and personalized medicine has significantly impacted the target humanized mice market. Humanized mice are invaluable in studying immune responses, cancer therapies, and the development of personalized treatment regimens. These models allow researchers to test therapies that are tailored to individual genetic profiles, improving treatment outcomes. With the rise of immuno-oncology and other targeted therapies, the demand for humanized mouse models to evaluate new treatments is expected to continue expanding, further driving market growth in the coming years.

5. Expansion of Healthcare Research and Clinical Trials: The expansion of healthcare research and clinical trials has led to a higher demand for humanized mice in preclinical testing. As healthcare research accelerates globally, there is an increasing need for reliable animal models that can mimic human disease and treatment responses accurately. Humanized mice provide the necessary tools for testing a wide range of therapeutic strategies, especially in oncology, immunology, and infectious diseases. The increasing number of clinical trials and research projects globally ensures the sustained growth of the humanized mice market as researchers continue to prioritize these models for their clinical relevance.

Challenges in the target humanized mice market are:

1. Ethical and Regulatory Concerns: Ethical and regulatory concerns surrounding the use of animals in research represent a significant challenge in the target humanized mice market. Stricter animal welfare regulations are being implemented globally, leading to greater scrutiny of the use of animal models in biomedical research. Researchers and companies must comply with ethical guidelines, such as the 3Rs (Replacement, Reduction, and Refinement), to minimize animal use and suffering. These regulations can increase the cost and complexity of developing and maintaining humanized mice models, as well as create potential delays in research timelines.

2. High Cost of Development and Maintenance: The development and maintenance of humanized mice models are expensive and resource-intensive. Producing humanized mice requires advanced genetic engineering techniques, specialized facilities, and highly skilled personnel, making them more costly than traditional animal models. Additionally, maintaining the health and genetic integrity of these mice over time requires significant investment in breeding, care, and monitoring. The high cost of development and maintenance may limit access to these models for smaller research institutions and companies, hindering widespread adoption and slowing market growth in some regions.

3. Limited Availability of Suitable Models: Another key challenge is the limited availability of suitable humanized mouse models for specific research needs. While significant progress has been made, the process of humanizing mice to accurately represent human diseases is still complex and resource-heavy. Researchers may find it difficult to access models that match specific disease conditions or genetic variations, limiting their ability to perform targeted research. This shortage of suitable models can delay research progress and restrict the potential applications of humanized mice, impacting market growth and the development of innovative therapies.

The target humanized mice market is driven by technological advancements in biotechnology, increasing investments in pharmaceutical and biotech industries, and a growing need for more accurate preclinical models. The expansion of immunotherapy and personalized medicine further fuels demand, alongside the increasing focus on healthcare research and clinical trials. However, challenges such as ethical and regulatory concerns, high development costs, and limited availability of specific models present hurdles to market growth. Navigating these challenges while leveraging the drivers will be essential for stakeholders to maximize the potential of humanized mice in advancing biomedical research and drug development.

List of Target Humanized Mice Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies target humanized mice companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the target humanized mice companies profiled in this report include-

• Charles River
• Jackson Laboratory
• Taconic Biosciences
• Gempharmatech
• Vitalstar Biotechnology
• GenOway
• Hanheng Biotechnology
• Cyagen Biosciences
• Beijing Biocytogen
• Shanghai Model Organisms Center

Target Humanized Mice Market by Segment

The study includes a forecast for the global target humanized mice market by type, application, and region.

Target Humanized Mice Market by Type [Value from 2019 to 2031]:

• Tumor Target
• Immune Checkpoint
• Complement System Targets
• Metabolic Target
• Other

Target Humanized Mice Market by Application [Value from 2019 to 2031]:

• Cancer Research
• Immunity Therapy
• Drug Screening

Target Humanized Mice Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Target Humanized Mice Market

The target humanized mice market is influenced by a range of technological, economic, and regulatory factors. Advances in biotechnology and genetic engineering have driven the development of humanized mouse models, which are essential for drug discovery and immunology research. Economic trends, such as increasing investment in life sciences and healthcare, further stimulate market growth. At the same time, regulatory factors, including ethical guidelines and animal welfare regulations, present challenges. Understanding the key drivers and challenges impacting this market is crucial for stakeholders to navigate the evolving landscape and harness the potential of humanized mice in biomedical research.

• United States: In the United States, the target humanized mice market has witnessed a surge in demand due to the country's dominance in biomedical research. Major pharmaceutical companies and biotech firms are investing heavily in humanized mouse models for preclinical testing, particularly for immunotherapies and personalized medicine. Additionally, collaborations between research institutions and private companies are accelerating advancements in genetically modified models that better mimic human disease conditions. The U.S. also leads in the development of advanced technologies for creating humanized mice, with significant contributions from gene-editing tools like CRISPR, driving the market forward.
• China: China is rapidly expanding its presence in the target humanized mice market, leveraging its large-scale manufacturing capabilities and research-driven approach. The country has seen a significant rise in biotech firms focused on producing humanized mice for drug discovery, particularly in cancer and autoimmune diseases. With growing investment in life sciences and a focus on biotechnology innovation, China is positioning itself as a competitive player in the market. Additionally, the government is actively supporting the biotechnology sector, fostering collaborations with international firms to advance humanized mouse technology and research outcomes.
• Germany: Germany's contributions to the target humanized mice market are largely driven by its strong research institutions and expertise in biomedical sciences. The country is a leader in genetic engineering techniques and has made significant progress in developing highly specialized humanized mouse models for studying complex diseases like Alzheimer's and cancer. German research institutions collaborate with major pharmaceutical companies to create more accurate models for drug testing and development. Germany is also focusing on the ethical considerations surrounding the use of humanized animals, ensuring that new models are not only scientifically advanced but also meet ethical standards for animal welfare.
• India: India is emerging as a growing player in the target humanized mice market, largely driven by increasing research investments in biomedical sciences. The demand for humanized mice models is rising as Indian researchers focus on personalized medicine and disease-specific therapies. With the expansion of biotechnology hubs in cities like Bangalore and Hyderabad, India is witnessing greater collaboration between academic institutions, pharmaceutical companies, and CROs (Contract Research Organizations). The cost-effectiveness of Indian research services, along with government support for biotech innovation, is accelerating the adoption of humanized mice models in the region.
• Japan: Japan has been at the forefront of advanced genetic research, and its contributions to the target humanized mice market reflect its leadership in biotechnological innovation. Japanese companies and universities are increasingly using humanized mice to study diseases like cancer, cardiovascular conditions, and infectious diseases. The market is growing as Japanese researchers focus on improving the accuracy and efficiency of humanized models, incorporating new genetic technologies to replicate human disease more effectively. Additionally, Japan's emphasis on ethical and sustainable scientific practices ensures the responsible use of humanized animals in research.

Features of the Global Target Humanized Mice Market

• Market Size Estimates: Target humanized mice market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Target humanized mice market size by type, application, and region in terms of value ($B).
• Regional Analysis: Target humanized mice market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the target humanized mice market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the target humanized mice market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the target humanized mice market by type (tumor target, immune checkpoint, complement system targets, metabolic target, and other), application (cancer research, immunity therapy, and drug screening), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Target Humanized Mice Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Tumor Target: Trends and Forecast (2019-2031)
• 4.4 Immune Checkpoint: Trends and Forecast (2019-2031)
• 4.5 Complement System Targets: Trends and Forecast (2019-2031)
• 4.6 Metabolic Target: Trends and Forecast (2019-2031)
• 4.7 Other: Trends and Forecast (2019-2031)

5. Global Target Humanized Mice Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Cancer Research: Trends and Forecast (2019-2031)
• 5.4 Immunity Therapy: Trends and Forecast (2019-2031)
• 5.5 Drug Screening: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Target Humanized Mice Market by Region

7. North American Target Humanized Mice Market

• 7.1 Overview
• 7.2 North American Target Humanized Mice Market by Type
• 7.3 North American Target Humanized Mice Market by Application
• 7.4 United States Target Humanized Mice Market
• 7.5 Mexican Target Humanized Mice Market
• 7.6 Canadian Target Humanized Mice Market

8. European Target Humanized Mice Market

• 8.1 Overview
• 8.2 European Target Humanized Mice Market by Type
• 8.3 European Target Humanized Mice Market by Application
• 8.4 German Target Humanized Mice Market
• 8.5 French Target Humanized Mice Market
• 8.6 Spanish Target Humanized Mice Market
• 8.7 Italian Target Humanized Mice Market
• 8.8 United Kingdom Target Humanized Mice Market

9. APAC Target Humanized Mice Market

• 9.1 Overview
• 9.2 APAC Target Humanized Mice Market by Type
• 9.3 APAC Target Humanized Mice Market by Application
• 9.4 Japanese Target Humanized Mice Market
• 9.5 Indian Target Humanized Mice Market
• 9.6 Chinese Target Humanized Mice Market
• 9.7 South Korean Target Humanized Mice Market
• 9.8 Indonesian Target Humanized Mice Market

10. ROW Target Humanized Mice Market

• 10.1 Overview
• 10.2 ROW Target Humanized Mice Market by Type
• 10.3 ROW Target Humanized Mice Market by Application
• 10.4 Middle Eastern Target Humanized Mice Market
• 10.5 South American Target Humanized Mice Market
• 10.6 African Target Humanized Mice Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Target Humanized Mice Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Charles River
  • Company Overview
  • Target Humanized Mice Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Jackson Laboratory
  • Company Overview
  • Target Humanized Mice Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Taconic Biosciences
  • Company Overview
  • Target Humanized Mice Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Gempharmatech
  • Company Overview
  • Target Humanized Mice Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Vitalstar Biotechnology
  • Company Overview
  • Target Humanized Mice Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 GenOway
  • Company Overview
  • Target Humanized Mice Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Hanheng Biotechnology
  • Company Overview
  • Target Humanized Mice Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Cyagen Biosciences
  • Company Overview
  • Target Humanized Mice Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Beijing Biocytogen
  • Company Overview
  • Target Humanized Mice Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Shanghai Model Organisms Center
  • Company Overview
  • Target Humanized Mice Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us